PET/MR Pre- and Post Radiotherapy for Cardiopulmonary Dysfunction Evaluation

Recruiting now · Not applicable

Conditions studied: Pulmonary Hypertension

In brief

Radiotherapy (RT) is a well-known and established therapy or adjuvant therapy for the treatment of thoracic cancer It uses a high energy radiation from x-rays, gamma rays and other charged particles that assist in damaging the cancer DNA. PET/MR as imaging biomarkers for cardiopulmonary dysfunction with a focus on Pulmonary hypertension (PH). Despite the measures taken to reduce the total radiation dose and to limit the radiation to normal tissues, there is evidence of transient or permanent radiotherapy induced myocardial and pulmonary dysfunction leading to PH in patients who receive radiotherapy above a certain threshold of received dose. To be able to Demonstrate correlation of combined PET/MR and plasma metabolomics markers in patients at risk of developing cardiopulmonary disfunction after RT.

Key facts

Study ID

NCT04901884

Run by

University Health Network, Toronto

People needed

40

Starts

2021-06-01

Expected to finish

2026-06-01

Last updated by the study team

2025-12-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 years
• Biopsy or otherwise clinically proven thoracic malignant mass which is intended to be treated with radio(chemo)therapy
• Intention to treat with radio(chemo)therapy with incidental cardiac irradiation of at least 25Gy.
• A negative urine or serum pregnancy test within the two week interval immediately prior to imaging, in women of child-bearing age.
• Ability to provide written informed consent to participate in the study (for all components of the trial: imaging with cardiac PET/MR, blood sampling for plasma metabolomics and circulating DNA).

You may not qualify if…

• Contraindication for MR as per current institutional guidelines.
• Contraindication for Gadolinium injection as per current institutional guidelines.
• Inability to lie supine for at least 45 minutes.
• Any patient who is pregnant or breastfeeding.
• Any patient with known hypersensitivity to 18F-FDG.

Where it is running

• University Health Network — Toronto, Ontario, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.